Although substantial future research is necessary in order to fully delineate the role of chemerin in cardiac pathology, including myocardial hypertrophy and heart failure, there is the potential of targeting the chemerin system as a therapeutic strategy for a number of cardiovascular pathologies [199]. Here, RARRES2 is linked to cardiac hypertrophy.